NEW YORK (360Dx) – Royal Philips announced on Tuesday that the Philips IntelliSite Pathology Solution has been approved by South Korea's regulators for use as a diagnostic tool.
The approval by South Korea's Ministry of Food and Drug Safety follows clearance by the US Food and Drug Administration in April 2017, and allows pathologists in that country to use digital pathology technology to assess and diagnose clinical histology cases digitally, instead of with a microscope, enhancing laboratory efficiency and quality, Philips said.
"Not only will implementing digital pathology promote increased efficiencies and collaboration between pathologists within South Korea and abroad," Marlon Thompson, general manager of Philips Digital Pathology Solutions, said in a statement, "but it also unlocks opportunity in the future for computational pathology, which aims to increase accuracies and enhance patient care."
The Philips IntelliSite Pathology Solution is an automated digital pathology image creation, viewing, and management system comprising a scanner and image management system. It is also CE-IVD marked and available globally for primary diagnostic use, Philips said. It received regulatory approval in Japan in December 2017, the company added.